Panbela Therapeutics enters research agreement University of Texas MD Anderson Cancer Center to evaluate polyamine metabolic inhibitor therapies to augment CAR-T mediated cytotoxicity against C19+ large B-cell lymphoma cell lines
Panbela Therapeutics, Inc. a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced it has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center for the evaluation of polyamine metabolic inhibitor therapies in combination with CAR-T cell therapies in preclinical models
The initial goal of these studies will be to ascertain if eflornithine and/or ivospemin treatment will augment CAR-T mediated cytotoxicity against CD19+ large B-cell lymphoma (LBCL) cell lines. Recently, a metabolite panel primarily consisting of polyamines was identified as predictive of poor response to anti-CD19 CAR T-cell therapy in relapsed refractory LBCL. Additionally, the polyamine (PA) uptake transport system is upregulated in LBCL and multiple myeloma (MM). Together, this suggests the potential for a polyamine targeted therapy in combination with CAR-T therapies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
